Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (PHIO) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PHIO · as of Sep 30, 2025
Ownership Breakdown
11
Institutional Holders
$467,442
Total Inst. Value
▲ $80,087 vs Q2
11.62M
Shares Outstanding
freeFloat 99.40%
188,486
13F Shares Held
▲ 23,764 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PHIO largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC pharmaceutical preparations | 87.6K | 1.60% | 1.60% | $217.32M | Nov 7, 2025 | ▲ 39.0K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 57.9K | 1.06% | 1.06% | $143.60M | Nov 12, 2025 | ▲ 212 |
CETERA INVESTMENT ADVISERS pharmaceutical preparations | 33.5K | 61.26% | 61.26% | $83.08M | Nov 14, 2025 | ▲ 1.0K |
MORGAN STANLEY pharmaceutical preparations | 6.0K | 10.97% | 10.97% | $14.88M | May 27, 2026 | — held |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 1.4K | 2.56% | 2.56% | $3.47M | Feb 3, 2026 | ▲ 1.4K |
SBI SECURITIES CO., LTD. pharmaceutical preparations | 1.1K | 2.01% | 2.01% | $2.73M | Nov 5, 2025 | ▼ 808 |
BNP PARIBAS ARBITRAGE, SNC pharmaceutical preparations | 413 | 0.76% | 0.76% | $1.02M | Nov 13, 2025 | NEW |
TOWER RESEARCH CAPITAL LLC (TRC) pharmaceutical preparations | 406 | 0.74% | 0.74% | $1.01M | Nov 14, 2025 | ▲ 406 |
ASSETMARK, INC pharmaceutical preparations | 110 | 0.20% | 0.20% | $273,000 | Nov 6, 2025 | — held |
UBS GROUP AG pharmaceutical preparations | 13 | 0.02% | 0.02% | $32,000 | Nov 13, 2025 | ▲ 13 |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
6
Increased
+41.9K shares1
New Positions
first time holders1
Decreased
−808 shares3
Sold Out
fully exitedNet shares change (top 50)
+41.1K
+41.9K / −808
Net new holders
+3
1 new / 3 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PHIO insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Lockshin Curtis director | Feb 5, 2026 | Award | 16,600 | — | — | 35.2K | Form 4 ↗ |
Freeman Jonathan E director | Feb 5, 2026 | Award | 16,600 | — | — | 32.7K | Form 4 ↗ |
Deming David H director | Feb 5, 2026 | Award | 23,800 | — | — | 37.8K | Form 4 ↗ |
Carson Lisa Cabott Chief Financial Officer | Feb 5, 2026 | Award | 47,000 | — | — | 94.0K | Form 4 ↗ |
BRADFORD PATRICIA A director | Feb 5, 2026 | Award | 18,500 | — | — | 45.7K | Form 4 ↗ |
Bitterman Robert J Chairman, Pres. & CEO | Feb 5, 2026 | Award | 120,000 | — | — | 411.4K | Form 4 ↗ |
Bitterman Robert J Chairman, Pres. & CEO | Dec 31, 2025 | Purchase | 5,000 | $1.03 | $5.2K | 291.4K | Form 4 ↗ |
Bitterman Robert J Chairman, Pres. & CEO | Dec 23, 2025 | Purchase | 5,000 | $1.02 | $5.1K | 286.4K | Form 4 ↗ |
Bitterman Robert J Chairman, Pres. & CEO | Nov 21, 2025 | Purchase | 5,000 | $1.14 | $5.7K | 281.4K | Form 4 ↗ |
Bitterman Robert J Chairman, Pres. & CEO | Nov 18, 2025 | Purchase | 5,000 | $1.27 | $6.3K | 276.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Phio Pharmaceuticals Corp. (PHIO) is primarily owned by institutional investors, who hold approximately 1.6% of total shares outstanding. Company insiders own approximately 0.60%, while retail and public investors account for the remaining 97.78%.
The largest institutional shareholder of Phio Pharmaceuticals Corp. is VANGUARD GROUP INC, holding approximately 87,628 shares — equal to 1.60% of outstanding shares — as of September 30, 2025.
A total of 11 institutional investors currently hold PHIO stock, with a combined institutional value of approximately $467,442 as of the most recent 13F filing period.
Frequently asked questions
PHIO ownershipPhio Pharmaceuticals Corp. (PHIO) is primarily owned by institutional investors, who hold approximately 1.6% of shares. The largest shareholder is VANGUARD GROUP INC with a 1.60% stake. Company insiders hold 0.60%. Data sourced from SEC Form 13F as of September 30, 2025.